Last reviewed · How we verify
10RAC+metronidazole
10RAC is a recombinant anti-cancer immunotherapy combined with metronidazole, an antimicrobial agent, to enhance anti-tumor immune response while treating anaerobic infections.
10RAC is a recombinant anti-cancer immunotherapy combined with metronidazole, an antimicrobial agent, to enhance anti-tumor immune response while controlling microbial burden. Used for Cancer (specific indication not clearly defined in available literature).
At a glance
| Generic name | 10RAC+metronidazole |
|---|---|
| Also known as | Pariet, Klaricid, Hiconcil, Flagyl |
| Sponsor | Buddhist Tzu Chi General Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
10RAC appears to be an immunotherapeutic agent designed to activate anti-tumor immunity, while metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain parasites. The combination may leverage metronidazole's immunomodulatory properties alongside 10RAC's direct anti-cancer mechanism, though the precise synergy is not well-characterized in public literature.
Approved indications
- Cancer (specific indication unclear from available data)
Common side effects
- Gastrointestinal disturbance (metronidazole-related)
- Metallic taste (metronidazole-related)
- Immune-related adverse events (10RAC-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 10RAC+metronidazole CI brief — competitive landscape report
- 10RAC+metronidazole updates RSS · CI watch RSS
- Buddhist Tzu Chi General Hospital portfolio CI